The Temozolomide–Doxorubicin paradox in Glioblastoma in vitro–in silico preclinical drug-screening

ME Oraiopoulou, E Tzamali, SE Psycharakis… - Scientific Reports, 2024 - nature.com
Adjuvant Temozolomide is considered the front-line Glioblastoma chemotherapeutic
treatment; yet not all patients respond. Latest trends in clinical trials usually refer to …

[HTML][HTML] Targeting chromosome 12q amplification in relapsed glioblastoma: the use of computational biological modeling to identify effective therapy—a case report

MP Castro, N Khanlou, A Fallah… - Annals of …, 2022 - ncbi.nlm.nih.gov
Background Relapsed glioblastoma (GBM) is often an imminently fatal condition with limited
therapeutic options. Computation biological modeling, ie, biosimulation, of comprehensive …

[HTML][HTML] Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy

EC Smyth, D Watson, MP Castro, B Nutzinger… - ESMO Gastrointestinal …, 2024 - Elsevier
Background Esophageal cancer [esophagogastric adenocarcinoma (OGA)] shows
heterogeneity at the molecular level, leading to lower efficacy rates and highlighting the …

Current status of precision oncology in adult glioblastoma

J Weller, AL Potthoff, T Zeyen, C Schaub, C Duffy… - Molecular … - Wiley Online Library
The concept of precision oncology, the application of targeted drugs based on
comprehensive molecular profiling, has revolutionized treatment strategies in oncology. This …

Caminando a hombros de gigantes: intersección entre la genómica y la IA

AF Cardona, AR Patiño, E Jaller, J Rodríguez… - Medicina, 2021 - revistamedicina.net
El presente manuscrito revisa las aplicaciones actuales de la inteligencia artificial (IA) en
genómica funcional. La reciente explosión de la IA sigue a los notables logros que ha …

[引用][C] Caminando a hombros de gigantes: intersección entre la genómica y la IA (Parte II).